Latest Research And Development News

Chimeric Therapeutics has progressed its CHM CDH17 and CHM CORE-NK clinical trials with promising safety and efficacy signals, while securing a key manufacturing partnership and appointing a renowned haematologist to its board. However, the company faces a pressing cash runway challenge.

InteliCare Holdings reported a $834,000 operating cash outflow for Q3 2025 but bolstered its balance sheet with a $1.8 million capital raise, positioning itself to sustain operations over the coming quarters.

Strategic Elements Ltd has marked a key milestone by successfully fabricating Energy Ink™ prototype cells in a commercial setting, while expanding its artificial intelligence ventures and maintaining a robust financial position.

BPH Global Limited secured $1.1 million in a recent placement and reported robust growth in its Indonesian seaweed operations, alongside promising advances in innovative seaweed-based products and strategic regional partnerships.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Stakk Limited reports a staggering 1,836% year-on-year increase in quarterly receipts, positioning itself on track to hit an $8 million annual recurring revenue target by mid-2026.

Hawsons Iron Limited reports solid progress on its Preliminary Feasibility Study for the Hawsons Iron Project, alongside promising metallurgical research with CSIRO and a successful $1.9 million capital raise.

HITIQ Ltd has secured a landmark order for its PROTEQT™ mouthguards at the Winter Olympics and launched in the UK consumer market, while advancing global validation and raising over A$2 million in capital.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.

Critica Limited has marked a significant milestone in its Jupiter rare earths project, commissioning a pilot plant and producing its first high-grade mixed rare earth oxide product, underscoring its path from resource to revenue.

Opthea has significantly reduced its operating costs and settled a key financial liability, positioning itself for a strategic review aimed at unlocking shareholder value.